CYDY CytoDyn

CytoDyn to Hold Conference Call on August 12 to Discuss Impressive Results from its Phase 2 COVID-19 Trial

CytoDyn to Hold Conference Call on August 12 to Discuss Impressive Results from its Phase 2 COVID-19 Trial

VANCOUVER, Washington, Aug. 11, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Jacob Lalezari, M.D., Senior Science Advisor, will host an investment community conference call on Wednesday, August 12, 2020, to provide a comprehensive overview of the compelling results from the Company’s recently completed Phase 2 CD10 trial for COVID-19 patients with mild-to-moderate symptoms, along with an update on its Phase 3 trial for COVID-19 patients with severe-to-critical indications and the regulatory path going forward.

Management will dedicate approximately 45 minutes to address questions from analysts and investors.

Date: Wednesday, August 12, 2020

Time: 1:00 pm PT / 4:00 pm ET

Dial-In: 877-407-8291 U.S. / 201-689-8345 International

A live audio webcast may also be accessed via CytoDyn’s corporate website at  under the Investors section/IR Calendar and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software. The webcast can also be accessed via the following link:

A replay of the conference call will be available until September 12, 2020. To access the replay, interested parties may dial 877-660-6853 (U.S.) / 201-612-7415 (International) and enter conference identification number 13708404.

CONTACTS

Investors:

Cristina De Leon

Office: 360.980.8524, ext. 106

Mobile: 503.214.0872

EN
11/08/2020

Underlying

CYDYCytoDyn

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CytoDyn

 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Surviv...

CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI response Durable Clinical Observations and Favorable Safety Profile Observed in Heavily Pretreated mTNBC Patients VANCOUVER, Washington, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibod...

February 20, 2026 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Announces Funding and Initiation of Expanded Access Program fo...

CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that a compassionate benefactor has formally committed funding to support ...

January 27, 2026 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

December 2025 Letter to Shareholders

December 2025 Letter to Shareholders VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your support, patience, and continued belief in CytoDyn’s (the “Company”) mission. I will remember 2025 as the year in which we first presented our astonishing survival observations and compelling data on the emerging role of leronlimab in solid tumor oncology. This past year has been one of disciplined execution, operational rebuilding, and meaningful scient...

December 16, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metast...

CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with leronlimab in combination with or followed by an immune checkpoint inhibitor VANCOUVER, Washington, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, ...

December 8, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Announces Resolution of Class Action Lawsuit

CytoDyn Announces Resolution of Class Action Lawsuit VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (mTNBC) and colorectal cancer (mCRC), today announced that it has reached an agreement in principle to resolve the previously disclosed securities class action lawsuit that was initially fil...

December 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch